A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults

NCT01478347 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Disease
Meningococcal Meningitis

Interventions

BIOLOGICAL: Recombinant meningococcal B + OMV NZ

Sponsor

Novartis Vaccines

Collaborators

[object Object]